Skip to content

AYALA PHARMACEUTICALS, INC.: net income or loss

Net income or loss for AYALA PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.

All AYALA PHARMACEUTICALS, INC. financial histories

What this measure means

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Exact concept: us-gaap:NetIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2002-03-01 to 2023-12-31. The SEC response was captured on 2026-09-22.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Net income or loss in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
2023-01-012023-12-31-48,072,000USD2024-04-1610-K · 0001493152-24-014822
2022-01-012022-12-31-38,013,000USD2024-04-1610-K · 0001493152-24-014822
2021-11-012022-10-31-14,359,000USD2023-02-1010-K · 0001493152-23-004167
2020-11-012021-10-31-17,862,000USD2023-02-1010-K · 0001493152-23-004167
2019-11-012020-10-31-26,469,000USD2022-02-1410-K · 0001493152-22-004469
2018-11-012019-10-31-16,612,000USD2021-01-2210-K · 0001493152-21-001656
2017-11-012018-10-31-66,515,000USD2019-12-2010-K · 0001493152-19-019523
2016-11-012017-10-31-93,435,000USD2019-01-1110-K · 0001493152-19-000489
2015-11-012016-10-31-73,556,230USD2017-12-2110-K · 0001493152-17-014889
2014-11-012015-10-31-47,031,118USD2017-12-2110-K · 0001493152-17-014889
2013-11-012014-10-31-16,525,314USD2017-01-0910-K · 0001493152-17-000250
2012-11-012013-10-31-19,986,826USD2015-01-0610-K · 0001493152-15-000050
2011-11-012012-10-31-12,069,687USD2014-01-2910-K · 0001144204-14-004716
2010-11-012011-10-31-8,115,740USD2014-01-2910-K · 0001144204-14-004716
2009-11-012010-10-31-10,812,200USD2014-01-2910-K · 0001144204-14-004716
2008-11-012009-10-31929,244USD2014-01-2910-K · 0001144204-14-004716
2007-11-012008-10-31-5,416,418USD2014-01-2910-K · 0001144204-14-004716
2006-11-012007-10-31-2,454,453USD2014-01-2910-K · 0001144204-14-004716
2005-11-012006-10-31-6,197,744USD2014-01-2910-K · 0001144204-14-004716
2004-11-012005-10-31-1,805,789USD2014-01-2910-K · 0001144204-14-004716
2004-01-012004-10-31-538,076USD2014-01-2910-K · 0001144204-14-004716
2003-01-012003-12-31-909,745USD2014-01-2910-K · 0001144204-14-004716
2002-03-012002-12-31-166,936USD2014-01-2910-K · 0001144204-14-004716

Related AYALA PHARMACEUTICALS, INC. histories

Inspect the source

Entity
AYALA PHARMACEUTICALS, INC. / CIK 0001100397
Captured
SEC response SHA-256
c79571e45bf72206000628dd6d16cc0b78424a189c2c21675f51fe12cd89a549

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001100397.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))